Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2012817
Max Phase: Preclinical
Molecular Formula: C31H43N7O4
Molecular Weight: 577.73
Molecule Type: Small molecule
Associated Items:
ID: ALA2012817
Max Phase: Preclinical
Molecular Formula: C31H43N7O4
Molecular Weight: 577.73
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CCC(=O)CCCCC[C@@H]1NC(=O)[C@@H](C)n2nncc2[C@H](CC(C)C)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC1=O
Standard InChI: InChI=1S/C31H43N7O4/c1-5-22(39)11-7-6-8-14-25-30(41)36-27(16-21-17-32-24-13-10-9-12-23(21)24)31(42)35-26(15-19(2)3)28-18-33-37-38(28)20(4)29(40)34-25/h9-10,12-13,17-20,25-27,32H,5-8,11,14-16H2,1-4H3,(H,34,40)(H,35,42)(H,36,41)/t20-,25+,26+,27+/m1/s1
Standard InChI Key: NKJANSUNVHHIIX-FLXBVFITSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 577.73 | Molecular Weight (Monoisotopic): 577.3377 | AlogP: 3.68 | #Rotatable Bonds: 11 |
Polar Surface Area: 150.87 | Molecular Species: NEUTRAL | HBA: 7 | HBD: 4 |
#RO5 Violations: 1 | HBA (Lipinski): 11 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 10.85 | CX Basic pKa: 0.34 | CX LogP: 3.52 | CX LogD: 3.52 |
Aromatic Rings: 3 | Heavy Atoms: 42 | QED Weighted: 0.26 | Np Likeness Score: 0.43 |
1. Hutt DM, Olsen CA, Vickers CJ, Herman D, Chalfant M, Montero A, Leman LJ, Burkle R, Maryanoff BE, Balch WE, Ghadiri MR.. (2011) Potential Agents for Treating Cystic Fibrosis: Cyclic Tetrapeptides that Restore Trafficking and Activity of ΔF508-CFTR., 2 (9): [PMID:21984958] [10.1021/ml200136e] |
2. Lai JI, Leman LJ, Ku S, Vickers CJ, Olsen CA, Montero A, Ghadiri MR, Gottesfeld JM.. (2017) Cyclic tetrapeptide HDAC inhibitors as potential therapeutics for spinal muscular atrophy: Screening with iPSC-derived neuronal cells., 27 (15): [PMID:28648462] [10.1016/j.bmcl.2017.06.027] |
Source(1):